Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05195775 · ClinicalTrials.gov registry record · Phase 2
Tadalafil as Adjuvant Therapy for DMD
A Phase 2 study of Duchenne Muscular Dystrophy, sponsored by University of Florida.
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05195775 is a Phase 2 study of Duchenne Muscular Dystrophy that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 25 participants, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05195775, a Phase 2 study of Duchenne Muscular Dystrophy, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This project will assess the vascular responsiveness in leg muscles of boys with Duchenne muscular dystrophy (DMD) to one single dose of tadalafil, a common vasodilator drug, using non-invasive techniques (MRI or Doppler ultrasound) and exercise testing. These findings will provide proof of concept for a subsequent intervention study to demonstrate efficacy of longer-term tadalafil to counter sympathetic vasoconstriction and slow disease progression in DMD. It will also inform whether a group of patients do not respond to the drug.
Conditions Studied
Interventions
- DRUG Tadalafil
Study Locations (1)
Florida
- University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-12-14 |
| Est. Completion | 2025-09-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05195775
The ClinicalTrials.gov registry entry for NCT05195775 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (94% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which Tadalafil is the first listed.
NCT05195775 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05195775 about?
NCT05195775 is a clinical study titled "Tadalafil as Adjuvant Therapy for DMD". This project will assess the vascular responsiveness in leg muscles of boys with Duchenne muscular dystrophy (DMD) to one single dose of tadalafil, a common vasodilator drug, using non-invasive techniques (MRI or Doppler ultrasound) and exercise testing. These findings will provide proof of concept ...
What is the current status of trial NCT05195775?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-12-14. Estimated completion is 2025-09-05.
What conditions does trial NCT05195775 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy.
What interventions are being tested in trial NCT05195775?
The interventions under investigation include: Tadalafil (DRUG).
Who is sponsoring clinical trial NCT05195775?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05195775 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
RECRUITING · Phase 2
-
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Vasodilator and Exercise Study for DMD (VASO-REx)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.